Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$10.8MMiss by $1.9M
EPS-$0.41Miss by $0.09
Revenue estimate$12.7M
EPS estimate-$0.32

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$13.2M
EPS estimate-$0.40

Financials

Q1 2026

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$1.89B-1.7%
Enterprise value$1.3B-19.0%
P/S36.4×+2.4×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Segments

By segment

See full
Single Reportable$10.8M+0.8%

Versus estimates

Revenue

Q1 2026$10.8MMiss by $1.9M
Q4 2025$13.3MMiss by $2.9MQ3 2025$14.5MMiss by $1.6MQ2 2025$13.5MMiss by $1.1MQ1 2025$10.6MMiss by $2.5MQ4 2024$17.1MMiss by $29.8K

Diluted EPS

Q1 2026-$0.41Miss by $0.09
Q4 2025-$0.29Beat by $0.04Q3 2025-$0.37Beat by $0.02Q2 2025-$0.39Miss by $0.04Q1 2025-$0.37Miss by $0.08Q4 2024-$0.29Miss by $0.05

Ask the moment Ocular Therapeutix reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Ocular Therapeutix report Q1 2026 earnings?
Ocular Therapeutix (OCUL) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Ocular Therapeutix's Q1 2026 revenue and EPS?
Ocular Therapeutix reported revenue of $10.8M and eps of $-0.41 for Q1 2026.
Did Ocular Therapeutix beat estimates in Q1 2026?
Revenue missed the consensus estimate of $12.7M by $1.9M. EPS missed the consensus estimate of $-0.32 by $0.09.
How did Ocular Therapeutix's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.4% from $10.6M a year earlier and eps declined 10.8% from $-0.37.
Where can I find Ocular Therapeutix's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-055241) and the 10-Q periodic report (0001104659-26-055256) directly on SEC EDGAR. The filing index links above go to sec.gov.